Wall Street Zen Downgrades Monte Rosa Therapeutics (NASDAQ:GLUE) to Sell

Monte Rosa Therapeutics (NASDAQ:GLUE) was downgraded by Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Saturday.

A number of other brokerages also recently commented on GLUE. Weiss Ratings reissued a “sell (d)” rating on shares of Monte Rosa Therapeutics in a research report on Monday, December 29th. Piper Sandler reaffirmed an “overweight” rating and set a $37.00 price target (up from $27.50) on shares of Monte Rosa Therapeutics in a research report on Wednesday, January 14th. TD Cowen reaffirmed a “buy” rating on shares of Monte Rosa Therapeutics in a report on Wednesday, January 7th. Jefferies Financial Group restated a “buy” rating and set a $31.00 price target on shares of Monte Rosa Therapeutics in a research note on Wednesday, January 7th. Finally, Wedbush reiterated an “outperform” rating and set a $37.00 price target on shares of Monte Rosa Therapeutics in a research note on Wednesday, January 7th. Six analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $32.80.

Monte Rosa Therapeutics Stock Down 2.7%

Monte Rosa Therapeutics stock opened at $15.63 on Friday. The firm has a market cap of $1.25 billion, a PE ratio of -33.98 and a beta of 1.63. Monte Rosa Therapeutics has a 52-week low of $3.50 and a 52-week high of $25.77. The company’s 50 day moving average is $19.62 and its two-hundred day moving average is $14.84.

Monte Rosa Therapeutics (NASDAQ:GLUE) last issued its quarterly earnings results on Tuesday, March 17th. The company reported ($0.55) EPS for the quarter, missing the consensus estimate of ($0.45) by ($0.10). Monte Rosa Therapeutics had a negative net margin of 31.23% and a negative return on equity of 15.12%. The business had revenue of $2.78 million during the quarter, compared to analysts’ expectations of $17.09 million. On average, equities research analysts anticipate that Monte Rosa Therapeutics will post -1.49 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, CEO Markus Warmuth sold 5,466 shares of Monte Rosa Therapeutics stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $17.92, for a total transaction of $97,950.72. Following the completion of the sale, the chief executive officer directly owned 613,471 shares in the company, valued at approximately $10,993,400.32. This trade represents a 0.88% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Edmund Dunn sold 25,164 shares of the business’s stock in a transaction that occurred on Friday, February 27th. The stock was sold at an average price of $18.10, for a total value of $455,468.40. Following the sale, the insider directly owned 22,693 shares in the company, valued at $410,743.30. This trade represents a 52.58% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 36,771 shares of company stock valued at $693,692. Insiders own 6.90% of the company’s stock.

Institutional Trading of Monte Rosa Therapeutics

Institutional investors have recently bought and sold shares of the company. AQR Capital Management LLC acquired a new stake in Monte Rosa Therapeutics in the first quarter valued at $1,065,000. Goldman Sachs Group Inc. boosted its position in shares of Monte Rosa Therapeutics by 122.7% in the 1st quarter. Goldman Sachs Group Inc. now owns 356,112 shares of the company’s stock worth $1,652,000 after buying an additional 196,238 shares in the last quarter. Acadian Asset Management LLC purchased a new stake in shares of Monte Rosa Therapeutics in the 1st quarter worth about $76,000. Geode Capital Management LLC grew its stake in Monte Rosa Therapeutics by 12.0% in the 2nd quarter. Geode Capital Management LLC now owns 1,124,160 shares of the company’s stock valued at $5,071,000 after acquiring an additional 120,098 shares during the last quarter. Finally, Intech Investment Management LLC grew its stake in Monte Rosa Therapeutics by 35.4% in the 2nd quarter. Intech Investment Management LLC now owns 29,870 shares of the company’s stock valued at $135,000 after acquiring an additional 7,808 shares during the last quarter. 79.96% of the stock is currently owned by hedge funds and other institutional investors.

About Monte Rosa Therapeutics

Monte Rosa Therapeutics is a biotechnology company focused on accelerating drug discovery through the integration of single-cell genomics and artificial intelligence. Founded in 2020 and headquartered in Cambridge, Massachusetts, the company has built a proprietary platform designed to identify novel therapeutic targets and optimize lead candidates for areas of high unmet medical need. By combining cutting-edge computational methods with comprehensive cellular profiling, Monte Rosa aims to streamline the preclinical development process and uncover insights into disease biology that might otherwise remain hidden.

The company’s main business activities center on using its AI-driven discovery engine to pursue programs in immuno-oncology and neuroscience.